›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Xpert® Bladder Cancer Monitor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Danaher CorpType:
CE Marked
Related tests:
2d
The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial (clinicaltrials.gov)
P2, N=262, Not yet recruiting, Chiti Arturo
New P2 trial • Liquid biopsy
|
Bladder EpiCheck® • Xpert® Bladder Cancer Monitor
7ms
Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer. (PubMed, Eur Urol Oncol)
UroFollow is the first urine marker-based randomized trial in low/intermediate-risk NMIBC patients. We conclude that 6-monthly marker-based follow-up after negative 3-mo WLC is safe in this cohort. Results of contemporary urine markers suggest that their potential for use in marker-based surveillance, however, requires prospective confirmation.
Journal
|
Bladder EpiCheck® • Xpert® Bladder Cancer Monitor
7ms
Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. (PubMed, Eur Urol)
Alternating cystoscopy with XBCM reduced the number of follow-up cystoscopies for high-grade NMIBC without affecting detection of any recurrence. The long-term oncological safety of this strategy needs to be validated over longer follow-up.
Journal • Biomarker testings
|
Xpert® Bladder Cancer Monitor
11ms
Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial. (PubMed, Eur Urol Open Sci)
The test was also more sensitive in detecting higher-grade cancers. More research is needed to confirm our results.
Journal
|
Xpert® Bladder Cancer Monitor
Share
